Story perspectives

FDA Expands Addyi Approval to Women Over 65

12/16/2025

Center

FDA Expands Addyi Approval

The U.S. Food and Drug Administration expanded Addyi's approval to postmenopausal women over 65.
The FDA announced the decision on December 15, 2025.
Addyi was first approved in 2015 for premenopausal women and carries dizziness and nausea as side effects, with a serious warning against alcohol.
The approval followed years of lobbying framed as a women's rights issue, while diagnosing low sexual desire remains complex, influenced by factors after menopause.

Left

FDA Proposes Sunscreen Update

The FDA proposes adding bemotrizinol to the list of approved sunscreen filters for American consumers.
Bemotrizinol is used in Europe and offers UVA protection and is gentler on sensitive skin.
Dermatologists are optimistic this move could raise U.S. sunscreens to European standards.
The proposal will undergo a public comment period before final approval.
FDA Commissioner Marty Makary stresses timely access to effective OTC products.

1 of 2

FDA Expands Addyi Approval

The U.S. Food and Drug Administration expanded Addyi's approval to postmenopausal women over 65.
The FDA announced the decision on December 15, 2025.
Addyi was first approved in 2015 for premenopausal women and carries dizziness and nausea as side effects, with a serious warning against alcohol.
The approval followed years of lobbying framed as a women's rights issue, while diagnosing low sexual desire remains complex, influenced by factors after menopause.

1 / 2